Peripheral nerve involvement in fukuyama congenital muscular dystrophy: a case report

Dae-Hyun Jang1, In Young Sung, Tae Sung Ko

  • 1Department of Rehabilitation, Incheon St Mary's Hospital, the Catholic University of Korea, Incheon, Korea.

Insights

Fukuyama congenital muscular dystrophy (FCMD) involves muscle weakness and brain abnormalities. This study links FCMD to peripheral nerve demyelination, suggesting fukutin protein impacts nerve health.

Area of Science:

  • Neurology
  • Genetics
  • Biochemistry

Background:

  • Fukuyama congenital muscular dystrophy (FCMD) is a genetic disorder characterized by muscle weakness and central nervous system (CNS) abnormalities.
  • It stems from mutations in the fukutin gene, affecting α-dystroglycan glycosylation, but fukutin's precise roles remain unclear.
  • α-dystroglycan is present in muscle, brain, and peripheral nerves, hinting at broader implications of fukutin deficiency.

Observation:

  • This report details a 7-year-old female diagnosed with FCMD.
  • The patient presented with generalized muscle weakness and CNS migration disturbances.
  • Additionally, she exhibited symptoms of demyelinating peripheral polyneuropathy.

Findings:

  • The study observed a correlation between FCMD and peripheral nerve demyelination in the patient.
  • Aberrant glycosylation of Schwann cell α-dystroglycan due to fukutin deficiency is proposed as the underlying mechanism.
  • This suggests fukutin plays a crucial role in peripheral nerve myelination.

Implications:

  • These findings expand the understanding of FCMD beyond muscle and CNS, highlighting its impact on peripheral nerves.
  • It suggests potential therapeutic targets for managing neurological complications in FCMD patients.
  • Further research into fukutin's function in myelination could reveal new insights into peripheral neuropathies.

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...